Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Dec;49(3):464-468.
doi: 10.1016/j.semarthrit.2019.04.009. Epub 2019 May 2.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Massimo Radin  1 , Savino Sciascia  2 , Doruk Erkan  3 , Vittorio Pengo  4 , Maria G Tektonidou  5 , Amaia Ugarte  6 , Pierluigi Meroni  7 , Lanlan Ji  8 , H Michael Belmont  9 , Hannah Cohen  10 , Guilherme Ramires de Jesús  11 , D Ware Branch  12 , Paul R Fortin  13 , Laura Andreoli  14 , Michelle Petri  15 , Esther Rodriguez  16 , Ignasi Rodriguez-Pinto  17 , Jason S Knight  18 , Tatsuya Atsumi  19 , Rohan Willis  20 , Emilio Gonzalez  20 , Rosario Lopez-Pedrera  21 , Ana Paula Rossi Gandara  22 , Margarete Borges Gualhardo Vendramini  22 , Alessandra Banzato  4 , Ecem Sevim  3 , Medha Barbhaiya  23 , Maria Efthymiou  10 , Ian Mackie  10 , Maria Laura Bertolaccini  24 , Danieli Andrade  22 ; APS ACTION
Affiliations
Multicenter Study

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Massimo Radin et al. Semin Arthritis Rheum. 2019 Dec.

Abstract

Objectives: To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis.

Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test.

Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05).

Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

Keywords: Antiphospholipid antibodies; Antiphospholipid syndrome; Cardiovascular; GAPSS; Risk stratification; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest: None declared

Figures

Figure 1.
Figure 1.
Levels of Adjusted Global Antiphospholipid Syndrome Score Among Different Study Subgroups
See this image and copyright information in PMC

References

    1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost [Internet]. 2006. February [cited 2016 Jul 4];4(2):295–306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16420554 - PubMed
    1. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) [Internet]. 2013. August [cited 2016 Sep 21];52(8):1397–403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23315788 - PubMed
    1. Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology [Internet]. 2018;(January):1–5. Available from: http://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumat... - DOI - PubMed
    1. Massimo Radin, Karen Schreiber, Irene Cecchi, Roccatello Dario CMJ and SS. The risk of ischaemic stroke in primary APS patients: a prospective study. Eur J Neurol. 2017;Accepted F. - PubMed
    1. Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum. 2018; - PubMed

Publication types

MeSH terms